Resistance to antiplatelet drugs: current status and future research

Bibliography

• GURBEL PA, BLIDEN KP, HAYES KM, TANTRY U: Platelet activation in myocardial ischemic syndromes. Expert Rev. Cardiovasc. Ther. (2004) 2:535–45.
   PubMedGoogle Scholar
• ••A recent comprehensive review about theimportance of platelet activation and reactivity, and its role in coronary artery diseases.
   Google Scholar
• JACKSON SP, NESBITT WS, KULKARNI S: Signaling events underlying thrombus formation. J. Thromb. Haemost. (2003) 1:1602–1612.
   PubMed Web of Science ®Google Scholar
• RUGGERI ZM: Platelets in atherothrombosis. Nat Med. (2002) 8:1227–1234.
   PubMed Web of Science ®Google Scholar
• ••Excellent review about the physiologicalrole of platelets during the development of atherothrombotic processes.
   Google Scholar
• LEVY-TOLEDANO S: Platelet signal transduction pathways: could we organize them into a 'hierarchy'? Haemostasis (1999) 29:4–15.
   Web of Science ®Google Scholar
• SHANKARAN H, ALEXANDRIDIS P, NEELAMEGHAM S: Aspects of hydrodynamic shear regulating shear-induced platelet activation and self-association of von Willebrand factor in suspension. Blood (2003) 101:2637–2645.
   PubMed Web of Science ®Google Scholar
• GAWAZ M: Role of platelets in coronary thrombosis and reperfitsion of ischemic myocardium. Cardiovasc. Res. (2004) 61:498–511.
   PubMed Web of Science ®Google Scholar
• SAMARA WM, GURBEL PA: The role of platelet receptors and adhesion molecules in coronary artery disease. Coron. Artery Dis. (2003) 14:65–79.
   PubMed Web of Science ®Google Scholar
• BRASS LF: Thrombin and platelet activation. Chest. (2003) 124(3 Suppl.):18S–25S.
   Google Scholar
• DORSAM RT, TULUC M, KUNAPULI SP: Role of protease-activated and ADP receptor subtypes in thrombin generation on human platelets. Thromb. Haemost. (2004) 2:804–812.
   Web of Science ®Google Scholar
• ADAM F, VERBEUREN TJ, FUCHERE JL, GUILLIN MC, JANDROT-PERRUS M: Thrombin-induced platelet PAR4 activation: role of glycoprotein TB and ADP. Thromb. Haemost. (2003) 1:798–804.
   Web of Science ®Google Scholar
• JIN J, QUINTON TM, ZHANG J, RITTENHOUSE SE, KUNAPULI SP: Adenosine diphosphate (ADP)-induced thromboxane A(2) generation in human platelets requires coordinated signaling through integrin a(II6)0(3) and ADP receptors. Blood (2002) 99:193–198.
   PubMed Web of Science ®Google Scholar
• DORSAM RT, KUNAPULI SP: Central role of the P2Y12 receptor in platelet activation. J. Clin. Invest. (2004) 113:340–345.
   PubMed Web of Science ®Google Scholar
• ••A very informative review about the role ofthe P2Y12 receptor during platelet activation and thombus formation.
   Google Scholar
• LI Z, ZHANG G, LE BRETON GC, GAO X, MALIK AB, DU X: Two waves of platelet secretion induced by thromboxane A2 receptor and a critical role for phosphoinositide 3-kinases. Biol. Chem. (2003) 278:30725–30731.
   Web of Science ®Google Scholar
• FREEDMAN JE, LOSCALZO J: Nitric oxide and its relationship to thrombotic disorders. Thromb. Haemost. (2003) 1:1183–1188.
   Web of Science ®Google Scholar
• LOSCALZO J: Nitric oxide insufficiency,platelet activation, and arterial thrombosis. Circ. Res. (2001) 88:756–762.
   PubMed Web of Science ®Google Scholar
• DAVIES MJ, THOMAS AC, KNAPMAN PA, HANGARTNER JR: Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation (1986) 73:418–427.
   PubMed Web of Science ®Google Scholar
• FALATI S, GROSS P, MERRILL-SKOLOFF G, FURIE BC, FURIE B: Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat. Med. (2002) 8:1175–1181.
   PubMed Web of Science ®Google Scholar
• GURBEL PA, KEREIAKES DJ, DALESANDRO MR, BAHR RD, O'CONNOR CM, SEREBRUANY VL: Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department. Am. Heart J. (2000) 139:320–328.
   PubMed Web of Science ®Google Scholar
• MATSAGAS MI, GEROULAKOS G, MIKHAILIDIS DP: The role of platelets in peripheral arterial disease: therapeutic implications. Ann. Vasc. Surg. (2002) 16:246–258.
   PubMed Web of Science ®Google Scholar
• MATETZKY S, SHENKMAN B, GUETTA Vet al.: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation (2004) 109:3171–3175.
   Google Scholar
• •• Important clinical evidence relating clopidogrel resistance to the occurrence of recurrent atherothrombotic events
   Google Scholar
• GURBEL PA, BLIDEN KP, ZAMAN KA, YOHO JA, HAYES KM, TANTRY US: Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the clopidogrel loading with eptifibatide to arrest the reactivity of platelets (CLEAR PLATELETS) study. Circulation (2005) 111:1153–1159.
   PubMed Web of Science ®Google Scholar
• ••Important clinical trial demonstrating therelation of lower myocardial necrosis marker release to the superior platelet inhibition by GP IIb/IlA inhibitor during elective coronary stenting.
   Google Scholar
• GURBEL PA, BLIDEN KP, SAMARA W, et al: The Clopidogrel Resistance and Stent Thrombosis (CREST) study. J. Am. Coll Cardiol (2005) In press.
   Google Scholar
• BLIDEN KP, TANTRY U, ZAMAN K, BASSI A. HAYES K, YOHO J, GURBEL PA: High platelet reactivity is a risk factor for post-discharge ischemic complications following elective coronary stenting. J. Am. Coll Cardiol (2005) 45:33A.
   Web of Science ®Google Scholar
• CLAGETT GP, SOBEL M, JACKSON MR, LIP GY, TANGELDER M, VERHAEGHE R: Antithrombotic therapy in peripheral arterial occlusive disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest (2004) 126:609S–626S.
   Google Scholar
• COSMI B, PALARETI G: Is there a role for oral anticoagulant therapy in patients with peripheral arterial disease? Curr. Drug Targets Cardiovasc. Haematol. Disord. (2004) 4:269–273.
   PubMedGoogle Scholar
• ARJOMAND H, COHEN M, EZEKOWITZ MD: Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with therosclerotic heart disease. J. Invasive Cardiol (2004) 16:271–278.
   PubMedGoogle Scholar
• RIBICHINI F, FERRERO V, WIJNS W: Reperfusion treatment of ST-elevation acute myocardial infarction. Prog. Cardiovasc. Dis. (2004) 47:131–157.
   PubMed Web of Science ®Google Scholar
• ANTITHROMBOTIC TRIALISTS' COLLABORATION: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. (2002) 324:71–86.
   PubMed Web of Science ®Google Scholar
• ••Important meta-analysis of trials studyingthe benefits of antiplatelet therapy.
   Google Scholar
• PATRONO C, COLLER B, FITZGERALD GA, HIRSH J, ROTH G: Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest (2004) 126(3 Suppl.):2345–2645.
   Google Scholar
• ••Important meta-analysis of trials studyingthe benefits of antiplatelet therapy.
   Google Scholar
• PATRONO C, BACHMANN F, BAIGENT C et al: Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur. Heart J. (2004) 25:166–181.
   Google Scholar
• ANTMAN EM, ANBE DT, ARMSTRONG PW et al: American College of Cardiology; American Heart Association Task Force on Practice Guidelines. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Circulation. (2004) 110:588–636.
   Google Scholar
• CAMPBELL CL, STEINHUBL SR: Variability in response to aspirin: do we understand the clinical relevance? J. Thromb. Haemost. (2005) 3(4):665–669.
   Web of Science ®Google Scholar
• GURBEL PA: Clopidogrel response variability and drug resistance. Haematologica (2004) 897(7 Suppl.):9–11.
   Google Scholar
• GONZALEZ-CONEJERO R, RIVERA J, CORRAL J, ACUNA C, GUERRERO JA, VICENTE V: Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke (2005) 36:276–280.
   PubMed Web of Science ®Google Scholar
• TANTRY U, BLIDEN K, HAYES K, YOHO J, GURBEL Pk Overestimation of aspirin resistance. J. Am. Coll Cardiol. (2005) 45:427A.
   Web of Science ®Google Scholar
• ••A recent study demonstrating the lowprevalence of aspirin resistance.
   Google Scholar
• LAU WC, GURBEL PA, WATKINS PB et al.: Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation (2004) 109:166–171.
   PubMed Web of Science ®Google Scholar
• TAUBERT D, KASTRATI A, HARLFINGER S et al.: Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb. Haemost. (2004) 92:311–316.
   PubMed Web of Science ®Google Scholar
• ZIMMERMANN N, WENK A, KIM U et al: Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation (2003) 108:542–547.
   PubMed Web of Science ®Google Scholar
• PAYNE DA, JONES CI, HAYES PD, WEBSTER SE, ROSS NAYLOR A, GOODALL AH: Platelet inhibition by aspirin is diminished in patients during carotid surgery: a form of transient aspirin resistance? Thromb. Haemost. (2004) 92:89–96.
   Google Scholar
• MACCHI L, CHRISTIAENS L, BRABANT S et al: Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb. Res. (2002) 107:45–49.
   PubMed Web of Science ®Google Scholar
• KAWASAKI T, OZEKI Y, IGAWA T, KAMBAYASHI J: Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke. (2000) 31:591–5.
   PubMed Web of Science ®Google Scholar
• SCHAFER Al: Genetic and acquired determinants of individual variability of response to antiplatelet drugs. Circulation (2003) 108:910–911.
   PubMed Web of Science ®Google Scholar
• O'DONNELL CJ, LARSON MG, FENG D et al: Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation (2001) 103:3051–3056.
   PubMed Web of Science ®Google Scholar
• BARRAGAN P, BOUVIER JL, ROQUEBERT PO et al: Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc. Interv. (2003) 59:295–302.
   PubMed Web of Science ®Google Scholar
• CATELLA-LAWSON F, REILLY MP, KAPOOR SC et al: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl. J. Med. (2001) 345:1809–1817.
   PubMed Web of Science ®Google Scholar
• ••Excellent article about the drug-druginteraction between aspirin and ibuprofen.
   Google Scholar
• PATRONO C: Aspirin resistance: definition, mechanisms and clinical read-outs. j Thromb. Haemost. (2003) 1:1710–1713.
   PubMed Web of Science ®Google Scholar
• ••Excellent review article about aspirinresistance.
   Google Scholar
• WALLER BF: Nonatherosclerotic coronary heart disease. In: Hurst 's the heart, 9th edn. Alexander RW, Schlant RC, Fuster V (Eds), McGraw Hill, New York (1998):1197–1240.
   Google Scholar
• WARLOW CP, DENNIS MS, VAN GIJN Jet al.: Stroke: a practical guide to management, 2nd edn. Blackwell Scientific Productions, Oxford (2001).
   Google Scholar
• SAKARIASSEN KS, HANSON SR, CADROY Y: Methods and models to evaluate shear-dependent and surface reactivity-dependent antithrombotic efficacy. Thromb. Res. (2001) 104:149–174.
   PubMed Web of Science ®Google Scholar
• PATRONO C: Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosage? Thromb. Res. (1998) 92:S7–S12.
   Google Scholar
• MICHELSON AD, CATTENEO M, EIKELBOOM JW et aL: Aspirin resistance: position paper of the working group on aspirin resistance, platelet physiology subcommittee of the scientific and standardization committee, international society on thrombosis and haemostasis. J. Thromb. Haemost. (2005): In press.
   Google Scholar
• VANE JR: Inhibition of prostaglandin syntheses as a mechanism of action of for aspirin-like drugs. Nat. New Biol. (1971) 231:232–235.
   PubMedGoogle Scholar
• ROTH GJ, STANFORD N, MAJERUS PW: Acetylation of prostaglandin synthase by aspirin. Proc. Natl. Acad. Sci. USA (1975) 72:3073–3077.
   PubMed Web of Science ®Google Scholar
• LOLL PJ, PICOT D, GARAVITO RM: The structural basis of aspirin activity inferred fron the crystal structure of inactivated prostaglandin H2 synthase. Nat. Struct. Biol. (1995) 2:637–643.
   PubMedGoogle Scholar
• PATRONO C, COLLER B, DALEN JE et al.: Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest (2001) 119(1 Suppl.):395–635.
   Google Scholar
• CIPOLLONE F, PATRIGNANI P, GRECO A et aL: Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation (1997) 96:1109–1116.
   PubMed Web of Science ®Google Scholar
• RATNATUNGA CP, EDMONDSON SF, REES GM, KOVACS IB: High-dose aspirin inhibits shear-induced platelet reaction involving thrombin generation. Circulation (1992) 85:1077–1082.
   PubMed Web of Science ®Google Scholar
• BUCHANAN MR, RISCHKE JA, HIRSH J: Aspirin inhibits platelet function independent of the acetylation of cyclo-oxygenase. Thromb. Res. (1982) 25:363–373.
   PubMed Web of Science ®Google Scholar
• SZCZEKLIK A, KRZANOWSKI M, GORA P, RADWAN J: Antiplatelet drugs and generation of thrombin in clotting blood. Blood. (1992) 80:2006–2011.
   PubMed Web of Science ®Google Scholar
• VALLES J, SANTOS MT, AZNAR J et al.:Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation (1998) 97:350–355.
   PubMed Web of Science ®Google Scholar
• SANTOS MT, VALLES J, AZNAR J, MARCUS AJ, BROEKMAN MJ, SAFIER LB: Prothrombotic effects of erythrocytes on platelet reactivity. Reduction by aspirin. Circulation (1997) 95:63–68.
   PubMed Web of Science ®Google Scholar
• HUSAIN S, ANDREWS NP, MULCAHY D, PANZA JA, QUYYUMI AA: Aspirin improves endothelial dysfunction in atherosclerosis. Circulation (1998) 97:716–720.
   PubMed Web of Science ®Google Scholar
• CATELLA F, HEALY D, LAWSON JA, FITZGERALD GA: 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc. NatL Acad. Sci. USA (1986) 83:5861–5865.
   PubMed Web of Science ®Google Scholar
• EIKELBOOM JW, HIRSH J, WEITZ JI, JOHNSTON M, YT Q, YUSUF S: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation (2002) 105:1650–5.
   PubMed Web of Science ®Google Scholar
• BARNATHAN ES, SCHWARTZ JS, TAYLOR Let al.: Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation (1987) 76:125–134.
   Google Scholar
• PETO R, GRAY R, COLLINS R et aL: Randomised trial of prophylactic daily aspirin in British male doctors. Br. Med. J. (1988) 296:313–316.
   PubMed Web of Science ®Google Scholar
• DYKEN ML, DYKEN ML, BARNETT HJ et al.: Low-dose aspirin and stroke. 'It ain't necessarily so'. Stroke (1992) 23:1395–1399.
   PubMed Web of Science ®Google Scholar
• [NO AUTHORS LISTED]: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS- 2: ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet (1988) 2:349–360.
   PubMedGoogle Scholar
• STEERING COMMITTEE OF THE PHYSICIANS' HEALTH STUDY RESEARCH GROUP: Final report on the aspirin component of the ongoing Physicians' Health Study. N EngL J. Med. (1989) 321:129–135.
   PubMed Web of Science ®Google Scholar
• IKONOMIDIS I, ANDREOTTI F, ECONOMOU E, STEFANADIS C, TOUTOUZAS P, NIHOYANNOPOULOS P: Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation (1999) 100:793–798.
   PubMed Web of Science ®Google Scholar
• YAN Y, PHILIPS DR: Aspirin response and failure in diabetic patients with cardiovascular disease. Curr. Opin. Pharm. (2005) 5:190–197.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, COOK NR, LEE, M et aL: A randomized trial of low-dose aspirin in the primary prevention of cardiovasacular disease in women. N EngL J. Med. (2005):352(13):1293–1304.
   PubMed Web of Science ®Google Scholar
• MEHTA J, MEHTA P, BURGER C, PEPINE CJ: Platelet aggregation studies in coronary artery disease. Past 4. Effect of aspirin. Atherosclerosis (1978) 31:169–175.
   PubMed Web of Science ®Google Scholar
• HURLEN M, SELJEFLOT I, ARNESEN H: The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction. Scand. Cardiovasc. J. (1998) 32:233–237.
   PubMed Web of Science ®Google Scholar
• BUCHANAN MR, BRISTER SJ: Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can. J. CardioL (1995) 11:221–227.
   PubMed Web of Science ®Google Scholar
• BUCHANAN MR, SCHWARTZ L, BOURASSA M, BRISTER SJ, PENISTON CM, BRAT INVESTIGATORS: Results of the BRAT study-a pilot study investigating the possible significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery. Can. J. CardioL (2000) 16:1385–1390.
   PubMed Web of Science ®Google Scholar
• GROTEMEYER KH, SCHARAFINSKI HW, HUSSTEDT IW: Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb. Res. (1993) 71:397–403.
   Google Scholar
• GUM PA, KOTTKE-MARCHANT K, POGGIO ED et al: Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. CardioL (2001) 88:230–235.
   PubMed Web of Science ®Google Scholar
• GUM PA, KOTTKE-MARCHANT K, WELSH PA, WHITE J, TOPOL EJ: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J. Am. Coll. CardioL (2003) 41:961–965.
   PubMed Web of Science ®Google Scholar
• WANG JC, AUCOIN-BARRY D, MANUELIAN D et aL: Incidence of aspirin nonresponsiveness using the Ultegra rapid platelet function assay-ASA. Am. J. CardioL (2003) 92:1492–1494.
   PubMed Web of Science ®Google Scholar
• CHEN W-H, LEE P-Y, NG W et aL: Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J. Am. Coll. CardioL (2004) 43:1122–1126.
   PubMedGoogle Scholar
• PULCINELLI FM, PIGNATELLI P, CELESTINI A, RIONDINO S, GAZZANIGA PP, VIOLI F: Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J. Am. Coll. CardioL (2004) 43:979–984.
   PubMed Web of Science ®Google Scholar
• HO WK, HANKEY GJ, EIKELBOOM JW: Is there a role for laboratory testing to identify patients at risk of aspirin treatment failure? Blood CoaguL Fibrinolysis. (2004) 15:129–30.
   Google Scholar
• EIKELBOOM JW, HANKEY GJ: Failure of aspirin to prevent atherothrombosis: potential mechanisms and implications for clinical practice. Am. J. Cardiovasc. Drugs. (2004) 4:57–67.
   PubMedGoogle Scholar
• MAREE AO AND FITZERALD DJ: Aspirin and coronary artery disease. Thromb. Haemost. (2004) 92:1175–1181.
   PubMed Web of Science ®Google Scholar
• MUELLER MR, SALAT A. STANGL P et al: Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb. Haemost. (1997) 78:1003–1007.
   PubMed Web of Science ®Google Scholar
• TSIARA S, ELISAF M, MIKHAILIDIS DP: Influence of smoking on predictors of vascular disease. Angiology (2003) 54:507–530.
   PubMed Web of Science ®Google Scholar
• ROCCA B, SECCHIERO P, CIABATTONI G et al.: Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc. Natl. Acad. Sci. USA (2002) 99:7634–7639.
   PubMed Web of Science ®Google Scholar
• MARCUS AJ, WEKSLER BB, JAFFE EA, BROEKMAN MJ: Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. J. Clin. Invest. (1980) 66:979–986.
   PubMed Web of Science ®Google Scholar
• WEBER AA, ZIMMERMANN KC, MEYER-KIRCHRATH J, SCHROR K: Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet (1999) 353:900.
   PubMed Web of Science ®Google Scholar
• DE CATERINA R, GIANNESSI D, BOEM A et al.: Equal antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction. Thromb. Haemost. (1985) 54:528–532.
   PubMed Web of Science ®Google Scholar
• DUTCH GROUP: A comparison of two doses of aspirin (30 mg versus 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. N EngL J. Med. (1991) 325:1261–1266.
   PubMed Web of Science ®Google Scholar
• TOHGI H, KONNO S, TAMURA K, KIMURA B, KAWANO K: Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke (1992) 23:1400–1403.
   PubMed Web of Science ®Google Scholar
• CAPRIE STREERING COMMITTEE: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet (1996) 348:1329–1339.
   PubMed Web of Science ®Google Scholar
• YUSUF S, ZHAO F, MEHTA SR et ell.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N EngL Med. (2001) 345:494–502.
   Google Scholar
• STEINHUBL SR, BERGER PB, MANN JT III et al.: Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 288:2411–2420.
   Google Scholar
• DIENER HC, BOGOUSSLAVSKY J, BRASS LM et al.: Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet (2004) 364:331–337.
   PubMed Web of Science ®Google Scholar
• BHATT DL, TOPOL EJ, CLOPIDOGREL FOR HIGH ATHEROTHROMBOTIC RISK AND ISCHEMIC STABILIZATION, MANAGEMENT, AND AVOIDANCE EXECUTIVE COMMITTEE: Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA) trial. Am. Heart J. (2004) 148:263–268.
   PubMed Web of Science ®Google Scholar
• MEHTA SR, YUSUF S, PETERS RJ et aL:Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet (2001) 358:527–533.
   PubMed Web of Science ®Google Scholar
• SAW P, COMBALBERT J, GAICH C et aL: The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb. Haemost. (1994) 72:313–317.
   PubMed Web of Science ®Google Scholar
• LAU WC, WASKELL LA, WATKINS PB et aL: Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation (2003) 107:32–37.
   PubMed Web of Science ®Google Scholar
• PEREILLO JM, MAFTOUH M, ANDRIEU A et aL: Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab. Dispos. (2002) 30:1288–95.
   PubMed Web of Science ®Google Scholar
• DING Z, KIM S, DORSAM RT, JIN J, KUNAPULI SP: Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood (2003) 101:3908–3914.
   PubMed Web of Science ®Google Scholar
• HOLLOPETER G, JANTZEN HM, VINCENT D et aL: Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature (2001) 409:202–207.
   PubMed Web of Science ®Google Scholar
• OHLMANN P, ECKLY A, FREUND M, CAZENAVE JP, OFFERMANNS S, GACHET C: ADP induces partial platelet aggregation without shape change and potentiates collagen-induced aggregation in the absence of Galphaq. Blood (2000) 96:2134–2139.
   PubMed Web of Science ®Google Scholar
• XIAO Z, THEROUX P: Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome./ Am. Coll. CardioL (2004) 43: 1982-1988.
   Google Scholar
• QUINN MJ, BHATT DL, ZIDAR F et al.: Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am. J. CardioL (2004) 93:679–684.
   PubMed Web of Science ®Google Scholar
• VIVEKANANTHAN DP, BHATT DL, CHEW DP et al.: Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am. J. CardioL (2004) 94:358–360.
   PubMed Web of Science ®Google Scholar
• HERMANN A, RAUCH BH, BRAUN M, SCHROR K, WEBER AA: Platelet CD40 ligand (CD4OL)-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets (2001) 12:74–82.
   PubMed Web of Science ®Google Scholar
• HANKEY GJ, SUDLOW CL, DUNBABIN DW: Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials. Stroke (2000) 31:1779–1784.
   PubMed Web of Science ®Google Scholar
• BHATT DL, CHEW DP, HIRSCH AT, RINGLEB PA, HACKE W, TOPOL EJ: Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation (2001) 103:363–368.
   PubMed Web of Science ®Google Scholar
• CANNON CP, CAPRIE INVESTIGATORS: Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). Am. J. CardioL (2002) 90:760–762.
   PubMed Web of Science ®Google Scholar
• BERTRAND ME, RUPPRECHT HJ, URBAN P, GERSHLICK AH, INVESTIGATORS FT: Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation (2000) 102:624–629.
   PubMed Web of Science ®Google Scholar
• ••Landmark clinical study demonstrating theresponse variability to clopidogrel and prevalence of clopidogrel resistance.
   Google Scholar
• GURBEL PA, BLIDEN KP, HIATT BL, O'CONNOR CM: Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation (2003) 107:2908–2913.
   PubMed Web of Science ®Google Scholar
• JAREMO P, LINDAHL TL, FRANSSON SG, RICHTER A: Individual variations of platelet inhibition after loading doses of clopidogrel. J. Intern. Med. (2002) 252:233–238.
   PubMed Web of Science ®Google Scholar
• MULLER I, BESTA F, SCHULZ C, MASSBERG S, SCHONIG A, GAWAZ M: Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb. Haemost. (2003) 89:783–787.
   PubMed Web of Science ®Google Scholar
• SAMARA -WM, BLIDEN KP, TANTRY US, GURBEL PA: The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb. Res. (2005) 115:89–94.
   PubMed Web of Science ®Google Scholar
• GURBEL Pk SAMARA WM, BLIDEN KP: Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. Platelets. (2004) 15:95–99.
   PubMed Web of Science ®Google Scholar
• GURBEL PA. BLIDEN KP: A new method of representing drug-induced platelet inhibition: better description of time course, response variability, non-response, and heightened activity. Platelets. (2003) 14:481–483.
   PubMed Web of Science ®Google Scholar
• GURBEL PA, BLIDEN KP: Interpretation of platelet inhibition by clopidogrel and the effect of non-responders. j Thromb. Haemost. (2003) 1:1318–1319.
   PubMed Web of Science ®Google Scholar
• MOBLEY JE, BRESEE SJ, WORTHAM DC, CRAFT RM, SNIDER CC, CARROLL RC: Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am. J. CardioL (2004) 93:456–458.
   PubMed Web of Science ®Google Scholar
• LEPANTALO A, VIRTANEN KS, HEIKKILA J, WARTIOVAARA U, LASSILA R: Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. Eur. Heart J. (2004) 25:476–483.
   PubMed Web of Science ®Google Scholar
• ANGIOLILLO DJ, FERNANDEZ-ORTIZ A, BERNARDO E et al.: Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb. Res. (2005) 115:101–108.
   PubMed Web of Science ®Google Scholar
• SEREBRUANY VI,, STEINHUBL SR, BERGER PB, MALININ Al, BHATT DL, TOPOL EJ: Variability in platelet responsiveness to clopidogrel among 544 individuals./ Am. Coll. CardioL (2005) 45:246–251
   PubMed Web of Science ®Google Scholar
• ALEIL B, RAVANAT C, CAZENAVE JP, ROCHOUX G, HEITZ A, GACHET C: Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. Thromb. Haemost. (2005) 3:85–92.
   Web of Science ®Google Scholar
• ANGIOLILLO DJ, FERNANDEZ-ORTIZ A, BERNARDO E et al.: PIA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood CoaguL Fibrinolysis. (2004) 15:89–93.
   PubMed Web of Science ®Google Scholar
• GURBEL PA, BLIDEN KP, HAYES KM, YOHO JA, HERZOG WR, TANTRY US: The relation of dosing to clopidogrel responsiveness and the incidence of high-treatment platelet aggregation in platelets undergoing coronary stenting. J. Am. Coll. Cardiol 42005) 45:1392–1396.
   PubMed Web of Science ®Google Scholar
• MULLER I, SEYFARTH M, RUDIGER S et al.: Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart (2001) 85:92–93.
   PubMed Web of Science ®Google Scholar
• KASTRATI k VON BECKERATH N, JOOST A, POGATSA-MURRAY G, GORCHAKOVA 0, SCHOMIG A: Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation (2004) 110: 1916-1919.
   Google Scholar
• GORCHAKOVA 0, VON BECKERATH N, GAWAZ M et aL: Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur. Heart J. (2004) 25:1898–1902.
   PubMed Web of Science ®Google Scholar
• ANGIOLLIO DJ, BERRANRDO E, RAMIERZ et al.: Pharmacogenetic modulation of clopidogrel antiplatelet effects:role of gene sequence variations of the CYP3A4 enzyme. J. Am. Coll. CardioL (2005) 45:414A.
   Web of Science ®Google Scholar
• LEVIN RI: Theriac found? Nitric oxide-aspirin and the search for the universal cure. J. Am. Coll. CardioL (2004) 44:642–643.
   PubMed Web of Science ®Google Scholar
• GRESELE P, MIGLIACCI R: Picotamide versus aspirin in diabetic patients with peripheral arterial disease: has David defeated Goliath? Eur. Heart J. (2004) 25:1769–1771.
   Google Scholar
• WALLENTIN L, JERNBERG T, LEESE PT et al.: Inhibition of platelet aggregation with prasugrel (CS-747, LY640315), a novel theinopyridine P2Y12 receptor anagonist, compared with clopidogrel in aspirin treated patients with atherosclerotic vascular disease. J. Am. Coll. CardioL (2004) 45:416A.
   Web of Science ®Google Scholar